Hepatitis E virus vaccine and method
AssigneeGenelabs Technologies, Inc.
InventorsGregory R. Reyes, Daniel W. Bradley, Jr-Shin Twu, Michael A. Purdy, Albert W. Tam, Krzysztof Z. Krawczynski, Patrice O. Yarbough
Life of this patent
Estimating the term…
Abstract
Antigen and antibody vaccine composition effective in preventing hepatitis E virus (HEV) infection are disclosed. The antigen composition includes a peptide corresponding to a carboxyl terminal end region of the capsid protein encoded by the second open reading frame 2 of the HEV genome. The composition is effective in preventing HEV infection after vaccination. The antibody composition contains an antibody effective to block HEV infection of human primary hepatocytes in culture.
Claims19
A vaccine composition used in immunizing an individual against hepatitis E virus (HEV) comprising, in a pharmacologically acceptable carrier,
- a peptide containing the C-terminal 42 amino acids of the capsid protein encoded by the second open reading frame of the HEV genome.
A vaccine composition containing antibodies capable of neutralizing hepatitis E virus (HEV) infection, as evidenced by the ability of the composition to block HEV infection of primary human hepatocyte cells in culture.
The method of 17, wherein the antibody in the composition is immunoreactive with a peptide containing the sequence identified by Sequence ID No. 15.
Dependencies are inferred from the claim text.